To identify a potential strategy for the treatment of R/R MCL, we performed cytotoxicity screening of inhibitors targeting DDR and cell cycle promotors in MCL cell lines with various mutations in ATM, TP53, and CDKN2A (Fig. 1c). This evidence concerns the gene ATM and mantle cell lymphoma.